Long-term experience with current disease-modifying drugs in multiple sclerosis

2006 ◽  
Vol 253 (S6) ◽  
pp. vi37-vi44 ◽  
Author(s):  
Corey C. Ford
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
Long Term Experience

scholarly journals Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)

2020 ◽  
Vol 13 ◽  
pp. 175628642092268 ◽  
Author(s):  
Francesco Patti ◽  
Andrea Visconti ◽  
Antonio Capacchione ◽  
Sanjeev Roy ◽  
Maria Trojano ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real World ◽  
Event Analysis ◽  
Treatment Change ◽  
Real World Data ◽  
Indirect Measure ◽  
Disease Modifying Drugs ◽  
Disease Modifying ◽  
Using Data

Background: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. Methods: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan–Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. Results: Time span under observation in the Italian MS Registry was 1–137 (median 80.3) months. In the total Italian patient population ( n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5–39.5) months. Conclusion: CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis

2013 ◽  
Vol 115 (2) ◽  
pp. 154-159 ◽  
Author(s):  
Yara Dadalti Fragoso ◽  
Mike Boggild ◽  
Miguel Angel Macias-Islas ◽  
Adriana Carra ◽  
Kirsty Deborah Schaerer ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Modifying Drugs ◽  
Disease Modifying

scholarly journals UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines

2019 ◽  
Vol 19 (2) ◽  
pp. 106-114 ◽  
Author(s):  
Ruth Dobson ◽  
Pooja Dassan ◽  
Megan Roberts ◽  
Gavin Giovannoni ◽  
Catherine Nelson-Piercy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Early Adulthood ◽  
Data Gathering ◽  
Consensus Guidelines ◽  
Limited Evidence ◽  
Disease Modifying Drugs ◽  
Modified Delphi ◽  
Specific Advice ◽  
Disease Modifying

Multiple sclerosis (MS) is more common in women than men and is most commonly diagnosed in early adulthood; thus, many patients will not have completed their families at the time of diagnosis. There is increasing awareness of the importance of early treatment in preventing long-term disability in MS. Delaying treatment until women with MS have completed their families can lead to the development of irreversible disability in at least some cases. It is therefore important to discuss family planning and pregnancy proactively. However, to date there is limited evidence to inform such discussions. We set out to develop consensus guidelines for the treatment of MS in pregnancy to encourage and facilitate discussions in this important area. The guidelines draw on available evidence from drug-specific pregnancy registers and published literature and have been scored by a panel of experts from a variety of disciplines using modified Delphi criteria. They cover prepregnancy counselling, management during pregnancy, delivery and anaesthetic options, postpartum advice and specific advice regarding currently licensed disease-modifying drugs. As the complexity and range of available disease-modifying drugs increase, further data gathering via a UK-wide MS pregnancy register is recommended.

Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review

CNS Drugs ◽  
2013 ◽  
Vol 27 (11) ◽  
pp. 955-961 ◽  
Author(s):  
Yara D. Fragoso ◽  
Tarso Adoni ◽  
Soniza V. Alves-Leon ◽  
Nério D. Azambuja ◽  
Amilton A. Barreira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Long Term Effects ◽  
Disease Modifying Drugs ◽  
Disease Modifying

scholarly journals HIV infection and multiple sclerosis: a case with unexpected “no evidence of disease activity” status

2021 ◽  
Vol 49 (3) ◽  
pp. 030006052199957
Author(s):  
Fernando Labella ◽  
Fernando Acebrón ◽  
María del Carmen Blanco-Valero ◽  
Alba Rodrígez-Martín ◽  
Ángela Monterde Ortega ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Hiv Infection ◽  
Disease Activity ◽  
Demyelinating Disease ◽  
Clinical Course ◽  
Disease Modifying Drugs ◽  
Immunodeficiency Virus ◽  
Relapsing Remitting ◽  
The Central Nervous System ◽  
Disease Modifying

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system whose etiology remains unclear. It has been suggested that MS can be triggered by certain viruses; however, human immunodeficiency virus (HIV) infection is associated with reduced incidence of MS. We present the case of a young patient diagnosed with active relapsing-remitting MS whose clinical course substantially improved following HIV infection and treatment. The patient achieved no evidence of disease activity status without any disease-modifying drugs. Both HIV-induced immunosuppression and antiretroviral therapy may have attenuated the clinical course in this patient.

scholarly journals Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis

2019 ◽  
Vol 25 (1) ◽  
pp. 113-121 ◽  
Author(s):  
Rishi J. Desai ◽  
Mufaddal Mahesri ◽  
Joshua J. Gagne ◽  
Eimir Hurley ◽  
Angela Tong ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Oral Disease ◽  
Disease Modifying Drugs ◽  
Utilization Patterns ◽  
Disease Modifying ◽  
Insured Patients
Sign in / Sign up

Export Citation Format

Share Document